FAQs

Where is Cogent Biosciences’ corporate headquarters?
Cogent Biosciences is headquartered at 200 CambridgePark Drive, Suite 2500, Cambridge, MA 02140. The main phone number is (617) 945-5576.
When did Cogent Biosciences go public?

Cogent Biosciences’ initial public offering (IPO) occurred on March 29, 2018

What is Cogent Biosciences’ fiscal year?
December 31
Where is Cogent Biosciences stock traded and what is the stock symbol?
Cogent Biosciences’  common stock is traded on the Nasdaq Global Select Market under the symbol COGT, and the CUSIP number for its common stock is 19240Q 201
Who is Cogent Biosciences’ transfer agent?

Computershare customer service can be accessed online at:

www-us.computershare.com/investor/Contact/Enquiry

Who is Cogent Biosciences’ independent auditor?
PricewaterhouseCoopers LLP
Why were the CVRs issued by Cogent and what is the tax treatment CVRs?

In connection with the Merger, announced on July 6, 2020, Cogent entered into a Contingent Value Rights Agreement, pursuant to which each holder of shares of common stock of record immediately prior to the effective time of the Merger is entitled to one contractual contingent value right ("CVR") for each share of common stock.  Each CVR entitles the holder thereof to receive certain common stock and/or cash payments from the net proceeds, if any, related to the disposition of Cogent’s legacy cell therapy assets within three years following the closing of the Merger. The CVRs are not transferable, except in certain limited circumstances as will be provided in the CVR Agreement, will not be certificated or evidenced by any instrument and will not be registered with the SEC or listed for trading on any exchange.

Cogent does not have a material amount of accumulated earnings and profits, and expects no or a small amount of current earnings and profits for the relevant taxable year. Thus, Cogent expects most or all of this distribution would be treated as other than a dividend for U.S. federal income tax purposes.

As per the CVR Agreement, after Cogent has a disposition of any of Cogent’s legacy cell therapy assets, stock payments relating to the CVRs are expected to be issued approximately fifty-five (55) days following the end of each calendar quarter that ends on or prior to December 31, 2020, and cash payments relating to the CVRs are expected to be issued approximately fifty-five (55) days following the end of each calendar quarter that ends on or following March 31, 2021.

PLEASE CONSULT YOUR TAX ADVISOR WITH RESPECT TO THE U.S. FEDERAL INCOME TAX CONSEQUENCES OF THE MERGER AND THE ISSUANCE OF THE CVRS IN LIGHT OF YOUR PERSONAL CIRCUMSTANCES AND THE PROPER CHARACTERIZATION OF THE RECEIPT OF THE CVRs.

Cogent Biosciences IRS Form 8937

How can I obtain further information or materials on Cogent Biosciences?
Cogent Biosciences’  SEC filings can be viewed at here or at www.sec.gov.
How can I receive email updates about Cogent?
Please sign up for email alerts using the button at the bottom of the page.
Whom should I contact regarding investor inquiries?

You can submit queries to Cogent Biosciences’ Investor Relations department by contacting

investorrelations@cogentbio.com